Affiliation:
1. Institute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter, Devon EX1 2LU, United Kingdom
2. Royal Devon and Exeter NHS Foundation Trust, Exeter, Devon EX2 7JU, United Kingdom
Abstract
Background: Metastasis still remains the major cause of therapeutic failure, poor prognosis
and high mortality in epithelial ovarian cancer (EOC) patients. Previously, we showed that EOC
cells secrete a range of factors with potential pro-angiogenic activity, in disease-relevant human
omental microvascular endothelial cells (HOMECs), including the lysosomal protease cathepsin L
(CathL). Thus, the aim of this study was to examine potential pro-proliferative and pro-migratory
effects of CathL in HOMECs and the activated signalling pathways, and whether these proangiogenic
responses are dependent on CathL-catalytic activity.
</P><P>
Methods: HOMECs proliferation was investigated using WST-1, BrdU and CyQUANT assays. Cell
migration was examined using a Cultrex Cell 96 transwell migration assay. Enzyme activity was assayed
at various pHs using the CathL-specific fluorogenic substrate FY-CHO. Activation of cell
signalling pathways was tested using a commercially available phosphokinase array and intact cellbased
ELISAs.
</P><P>
Results: We showed for the first time that CathL has a potent pro-proliferative and pro-migratory
effect on HOMECs. For instance, CathL significantly increases HOMEC proliferation (134.8±14.7%
vs control 100%) and migration (146.6±17.3% vs control 100%). Our data strongly suggest that
these proangiogenic effects of CathL are mediated via a non-proteolytic mechanism. Finally, we
show that CathL-induced activation of the ERK1/2 pathway is involved in inducing these cellular
effects in HOMECs.
</P><P>
Conclusion: These data suggest that CathL acts as an extracellular ligand and plays an important
pro-angiogenic, and thus pro-metastatic, role during EOC metastasis to the omentum, by activating
the omental microvasculature, and thus can potentially be targeted therapeutically in the future.
Publisher
Bentham Science Publishers Ltd.
Subject
Cancer Research,Drug Discovery,Pharmacology,Oncology
Reference50 articles.
1. . Ovarian cancer development and metastasis.
2. van der Zee AG, de Vries EG, de Jong S, Timmer-Bosscha H, ten Hoor KA, den Dunnen WF, Hollema H, Reyners AK. Multiple VEGF family members are simultaneously expressed in ovarian cancer: a proposed model for bevacizumab resistance.
3. Liu Y, Sun Y, He X. Expression of Ets-1, Ang-2 and maspin in ovarian cancer and their role in tumor angiogenesis.
4. Miyamoto S, Suzuki SO, Oki E, Yagi H, Sonoda K, Yamazaki A, Mizushima H, Maehara Y, Mekada E, Nakano H. Clinical significance of heparin-binding epidermal growth factor-like growth factor and a disintegrin and metalloprotease 17 expression in human ovarian cancer.
5. De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL, Simons JW. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases.
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献